GlassScriptPhysician profile
Waluana D Tomlin
NPI 1417164930
$3,036.15
in general payments reported to CMS, 2019-2025
21 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.39 · 2023: $351 · 2024: $738 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,021.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $982.95 | 2023-2025 | Fasenra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $521.25 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $296.92 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $160.44 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $155.19 | 2024-2025 | Tyvaso, Tyvaso |
| Horizon Therapeutics Plc | $124.97 | 2023 | Krystexxa |
| Genzyme Corporation | $101.41 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $99.99 | 2024-2025 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $82.47 | 2023-2024 | Yupelri |
| Baxter Healthcare | $79.46 | 2024-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Volara System |
| Viatris Specialty LLC | $58.09 | 2025 | Yupelri |
| Electromed, INC. | $55.27 | 2024-2025 | Smartvest |
| Novo Nordisk INC | $49.23 | 2024 | Rybelsus, Ozempic |
| Ardelyx, INC. | $48.89 | 2024 | Ibsrela |
| Insmed, INC. | $44.80 | 2025 | Arikayce, Brinsupri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.77 | 2023-2025 | |
| Liquidia Technologies, INC. | $33.33 | 2025 | Yutrepia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.15 | 2025 | Ofev, Jascayd |
| Akebia Therapeutics INC | $27.77 | 2024 | Auryxia |
| Novartis Pharmaceuticals Corporation | $19.06 | 2024 | |
| 3b Medical, INC. | $17.74 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waluana Tomlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.